A genetic basis for cancer sex differences revealed in Xp11 translocation renal cell carcinoma
M. Achom, A. Sadagopan, C. Bao, F. McBride, Q. Xu, P. Konda, R. W. Tourdot, J. Li, M. Nakhoul, D. Gallant, U. A. Ahmed, J. O'Toole, D. Freeman, G.-S. M. Lee, J. Hecht, E. Kauffman, D. J. Einstein, T. K. Choueiri, C.-Z. Zhang, S. R. Viswanathan
Abstract
Xp11 translocation renal cell carcinoma (tRCC) is a female-predominant kidney cancer driven by translocations between the TFE3 gene on chromosome Xp11.2 and partner genes located on either chrX or on autosomes. The rearrangement processes that underlie TFE3 fusions, and whether they are linked to the female sex bias of this cancer, are largely unexplored. Moreover, whether oncogenic TFE3 fusions arise from both the active and inactive X chromosomes in females remains unknown. Here we address these questions by haplotype-specific analyses of whole-genome sequences of 29 tRCC samples from 15 patients and by re-analysis of 145 published tRCC whole-exome sequences. We show that TFE3 fusions universally arise as reciprocal translocations with minimal DNA loss or insertion at paired break ends. Strikingly, we observe a near exact 2:1 female:male ratio in TFE3 fusions arising via X:autosomal translocation (but not via X inversion), which accounts for the female predominance of tRCC. This 2:1 ratio is at least partially attributable to oncogenic fusions involving the inactive X chromosome and is accompanied by partial re-activation of silenced chrX genes on the rearranged chromosome. Our results highlight how somatic alterations involving the X chromosome place unique constraints on tumor initiation and exemplify how genetic rearrangements of the sex chromosomes can underlie cancer sex differences.
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Loss of the Y chromosome is transcriptionally silent in clear cell renal cell carcinoma and across cancer entities
Alex Waterhölter, Rebecca Scholz, … Ian J. Frew·bioRxiv·Oct 9, 2026
- TFE3 fusions drive expression of CD44 and SPP1 in Translocation Renal Cell Carcinoma
Kaushal V. Asrani, Juhyung Woo, … Tamara Lotan·bioRxiv·Sep 22, 2026
- Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma
Z. Bakouny, A. Sadagopan, … S. R. Viswanathan·bioRxiv·Apr 14, 2021
- TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma
Jiao Li, Kaimeng Huang, … Srinivas Raghavan Viswanathan·Nature MetabolismPeer-reviewed·Feb 6, 2025
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Prathyusha Konda, Alexandra J. Wakolbinger, … Srinivas Raghavan Viswanathan·Nature CommunicationsPeer-reviewed·Aug 26, 2026
- Sexually dimorphic effects of mutations in ccRCC driver genes in renal proximal tubule cells
Antonella Catalano, Constanze Kainz, … Mojca Adlesic·bioRxiv·May 26, 2026